221 related articles for article (PubMed ID: 27846256)
1. Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012).
Crank MC; Wilson EM; Novik L; Enama ME; Hendel CS; Gu W; Nason MC; Bailer RT; Nabel GJ; McDermott AB; Mascola JR; Koup RA; Ledgerwood JE; Graham BS;
PLoS One; 2016; 11(11):e0166393. PubMed ID: 27846256
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.
Jaoko W; Karita E; Kayitenkore K; Omosa-Manyonyi G; Allen S; Than S; Adams EM; Graham BS; Koup RA; Bailer RT; Smith C; Dally L; Farah B; Anzala O; Muvunyi CM; Bizimana J; Tarragona-Fiol T; Bergin PJ; Hayes P; Ho M; Loughran K; Komaroff W; Stevens G; Thomson H; Boaz MJ; Cox JH; Schmidt C; Gilmour J; Nabel GJ; Fast P; Bwayo J
PLoS One; 2010 Sep; 5(9):e12873. PubMed ID: 20877623
[TBL] [Abstract][Full Text] [Related]
3. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).
Churchyard GJ; Morgan C; Adams E; Hural J; Graham BS; Moodie Z; Grove D; Gray G; Bekker LG; McElrath MJ; Tomaras GD; Goepfert P; Kalams S; Baden LR; Lally M; Dolin R; Blattner W; Kalichman A; Figueroa JP; Pape J; Schechter M; Defawe O; De Rosa SC; Montefiori DC; Nabel GJ; Corey L; Keefer MC;
PLoS One; 2011; 6(8):e21225. PubMed ID: 21857901
[TBL] [Abstract][Full Text] [Related]
4. Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals.
Fuchs JD; Bart PA; Frahm N; Morgan C; Gilbert PB; Kochar N; DeRosa SC; Tomaras GD; Wagner TM; Baden LR; Koblin BA; Rouphael NG; Kalams SA; Keefer MC; Goepfert PA; Sobieszczyk ME; Mayer KH; Swann E; Liao HX; Haynes BF; Graham BS; McElrath MJ;
J AIDS Clin Res; 2015 May; 6(5):. PubMed ID: 26587311
[TBL] [Abstract][Full Text] [Related]
5. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.
Koup RA; Roederer M; Lamoreaux L; Fischer J; Novik L; Nason MC; Larkin BD; Enama ME; Ledgerwood JE; Bailer RT; Mascola JR; Nabel GJ; Graham BS; ;
PLoS One; 2010 Feb; 5(2):e9015. PubMed ID: 20126394
[TBL] [Abstract][Full Text] [Related]
6. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).
Kibuuka H; Kimutai R; Maboko L; Sawe F; Schunk MS; Kroidl A; Shaffer D; Eller LA; Kibaya R; Eller MA; Schindler KB; Schuetz A; Millard M; Kroll J; Dally L; Hoelscher M; Bailer R; Cox JH; Marovich M; Birx DL; Graham BS; Michael NL; de Souza MS; Robb ML
J Infect Dis; 2010 Feb; 201(4):600-7. PubMed ID: 20078213
[TBL] [Abstract][Full Text] [Related]
7. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
[TBL] [Abstract][Full Text] [Related]
8. DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial.
Graham BS; Enama ME; Nason MC; Gordon IJ; Peel SA; Ledgerwood JE; Plummer SA; Mascola JR; Bailer RT; Roederer M; Koup RA; Nabel GJ;
PLoS One; 2013; 8(4):e59340. PubMed ID: 23577062
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial.
Koblin BA; Casapia M; Morgan C; Qin L; Wang ZM; Defawe OD; Baden L; Goepfert P; Tomaras GD; Montefiori DC; McElrath MJ; Saavedra L; Lau CY; Graham BS;
PLoS One; 2011; 6(9):e24517. PubMed ID: 21931737
[TBL] [Abstract][Full Text] [Related]
10. Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011).
Enama ME; Ledgerwood JE; Novik L; Nason MC; Gordon IJ; Holman L; Bailer RT; Roederer M; Koup RA; Mascola JR; Nabel GJ; Graham BS;
PLoS One; 2014; 9(3):e91366. PubMed ID: 24621858
[TBL] [Abstract][Full Text] [Related]
11. HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial.
Bart PA; Huang Y; Karuna ST; Chappuis S; Gaillard J; Kochar N; Shen X; Allen MA; Ding S; Hural J; Liao HX; Haynes BF; Graham BS; Gilbert PB; McElrath MJ; Montefiori DC; Tomaras GD; Pantaleo G; Frahm N
J Clin Invest; 2014 Nov; 124(11):4843-56. PubMed ID: 25271627
[TBL] [Abstract][Full Text] [Related]
12. Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial.
Sarwar UN; Novik L; Enama ME; Plummer SA; Koup RA; Nason MC; Bailer RT; McDermott AB; Roederer M; Mascola JR; Ledgerwood JE; Graham BS;
PLoS One; 2014; 9(9):e106240. PubMed ID: 25264782
[TBL] [Abstract][Full Text] [Related]
13. Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.
Bridge SH; Sharpe SA; Dennis MJ; Dowall SD; Getty B; Anson DS; Skinner MA; Stewart JP; Blanchard TJ
Virol J; 2011 Sep; 8():429. PubMed ID: 21899739
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.
Baden LR; Karita E; Mutua G; Bekker LG; Gray G; Page-Shipp L; Walsh SR; Nyombayire J; Anzala O; Roux S; Laher F; Innes C; Seaman MS; Cohen YZ; Peter L; Frahm N; McElrath MJ; Hayes P; Swann E; Grunenberg N; Grazia-Pau M; Weijtens M; Sadoff J; Dally L; Lombardo A; Gilmour J; Cox J; Dolin R; Fast P; Barouch DH; Laufer DS;
Ann Intern Med; 2016 Mar; 164(5):313-22. PubMed ID: 26833336
[TBL] [Abstract][Full Text] [Related]
15. Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy.
Lhomme E; Richert L; Moodie Z; Pasin C; Kalams SA; Morgan C; Self S; De Rosa SC; Thiébaut R
PLoS One; 2016; 11(4):e0152952. PubMed ID: 27124598
[TBL] [Abstract][Full Text] [Related]
16. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).
Stephenson KE; Wegmann F; Tomaka F; Walsh SR; Tan CS; Lavreys L; Ansel JL; Kanjilal DG; Jaegle K; Nkolola JP; Peter L; Fogel R; Bradshaw C; Tyler A; Makoni T; Howe L; Quijada D; Chandrashekar A; Bondzie EA; Borducchi EN; Yanosick KE; Hendriks J; Nijs S; Truyers C; Tolboom J; Zahn RC; Seaman MS; Alter G; Stieh DJ; Pau MG; Schuitemaker H; Barouch DH
Lancet HIV; 2020 Jun; 7(6):e410-e421. PubMed ID: 32078815
[TBL] [Abstract][Full Text] [Related]
17. Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.
Walsh SR; Moodie Z; Fiore-Gartland AJ; Morgan C; Wilck MB; Hammer SM; Buchbinder SP; Kalams SA; Goepfert PA; Mulligan MJ; Keefer MC; Baden LR; Swann EM; Grant S; Ahmed H; Li F; Hertz T; Self SG; Friedrich D; Frahm N; Liao HX; Montefiori DC; Tomaras GD; McElrath MJ; Hural J; Graham BS; Jin X;
J Infect Dis; 2016 Feb; 213(4):541-50. PubMed ID: 26475930
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial.
Pantaleo G; Janes H; Karuna S; Grant S; Ouedraogo GL; Allen M; Tomaras GD; Frahm N; Montefiori DC; Ferrari G; Ding S; Lee C; Robb ML; Esteban M; Wagner R; Bart PA; Rettby N; McElrath MJ; Gilbert PB; Kublin JG; Corey L;
Lancet HIV; 2019 Nov; 6(11):e737-e749. PubMed ID: 31601541
[TBL] [Abstract][Full Text] [Related]
19. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.
Bakari M; Aboud S; Nilsson C; Francis J; Buma D; Moshiro C; Aris EA; Lyamuya EF; Janabi M; Godoy-Ramirez K; Joachim A; Polonis VR; Bråve A; Earl P; Robb M; Marovich M; Wahren B; Pallangyo K; Biberfeld G; Mhalu F; Sandström E
Vaccine; 2011 Oct; 29(46):8417-28. PubMed ID: 21864626
[TBL] [Abstract][Full Text] [Related]
20. HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects.
Gach JS; Gorlani A; Dotsey EY; Becerra JC; Anderson CT; Berzins B; Felgner PL; Forthal DN; Deeks SG; Wilkin TJ; Casazza JP; Koup RA; Katlama C; Autran B; Murphy RL; Achenbach CJ
PLoS One; 2016; 11(8):e0160341. PubMed ID: 27500639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
